Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study

NCT05039840 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05039840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 10, 2021
Completion date
November 24, 2026
Enrollment
109 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus